Trade Tensions with China Drive Healthcare Stocks Lower
10/11/2025, 7:03:03 PM | China | United States
Medical
Healthcare and device stocks fell after US-China tensions and China’s rare-earth export controls raised supply-chain and cost concerns.
Stocks in several healthcare and medical-device companies slid in afternoon trading after escalating US-China tensions and comments from President Donald Trump hinted at canceling a meeting with President Xi.
Market participants reacted sharply when China moved to impose export controls on rare-earth minerals — inputs critical to high-tech manufacturing — raising concerns about supply-chain disruption and higher component costs for technology-dependent firms.
Notable moves included Myriad Genetics (NASDAQ:MYGN) down ~3.7%, Omnicell (NASDAQ:OMCL) down ~3.8%, Globus Medical (NYSE:GMED) down ~3.8%, Repligen (NASDAQ:RGEN) down ~3.0%, and Teleflex (NYSE:TFX) down ~3.8%.
Globus Medical merits closer attention: the stock has been relatively low-volatility, with few >5% moves over the past year, so today’s decline signals investor concern. Earlier this year the unexpected resignation of CEO Daniel Scavilla produced a larger drop; the company has since promoted internal leadership and reaffirmed full-year 2025 revenue and EPS guidance. GMED is down about 30.6% year-to-date, trading near $56.81 and roughly 39% below its 52-week high.
Traders and investors are weighing the near-term operational risk from mineral controls against longer-term fundamentals, creating potential entry points amid elevated volatility.